National and Kapodistrian University of Athens
Κλινική σημασία της έκφρασης του υποδοχέα PXR σε καρκινώματα παγκρέατος
Abstract
dc:descriptionINTRODUCTION: Pregnane X Receptor (PXR) is a member of the nuclear receptor superfamily, expressed in liver, intestine and other tissues. This nuclear receptor is implicated in the homeostasis of numerous endobiotics, such as glucose, lipids, steroids and bile acids, as well as regulation of xenobiotic metabolism and drug-drug interactions. New roles for PXR have been established in inflammatory bowel disease, bone homeostasis, liver steatosis, antifibrogenesis and oxidative stress. PXR has been involved in human malignancy, either by directly affecting carcinogenesis or by inducing drug-drug interactions and chemotherapy resistance. More specifically, pancreatic cancer is one of the most aggressive human cancers, with more than 200 000 deaths worldwide every year. Despite recent efforts, conventional treatment approaches, such as surgery and classic chemotherapy, have only slightly improved patient outcomes. OBJECTIVES: The present study aimed to assess the clinical significance of PXR expression in pancreatic adenocarcinoma. METHODS: Pregnane X receptor and its heterodimers' PXR/retinoid X receptor alpha (RXR-alpha), RXR-beta, and RXR-gamma expression were assessed immunohistochemically on tumoral samples from 55 pancreatic adenocarcinoma patients and were associated with clinicopathologic parameters, tumor proliferative capacity, and patients' survival. RESULTS: Enhanced PXR expression was noted in 24 (43.6%) of 55 pancreatic adenocarcinoma cases. Pancreatic adenocarcinoma patients presenting increased histological grade of tumor differentiation showed a significant increased incidence of elevated PXR expression (p=0.023). Enhanced PXR/RXR-beta expression was significantly associated with smaller tumor size and earlier clinical stage (p=0.005 and p=0.003, respectively). Elevated PXR/RXR-gamma expression was significantly associated with smaller tumor size and earlier clinical stage (p=0.012 and p=0.014, respectively) and borderline with the absence of lymph node metastases (p=0.056). In addition, pancreatic adenocarcinoma patients presenting enhanced PXR/RXR-gamma expression showed marginally longer survival times compared with those with decreased expression (log-rank test, p=0.053). CONCLUSIONS: This study provided evidence that PXR and its copartners' overexpression may be associated with favorable clinicopathologic parameters and better outcome of patients with pancreatic adenocarcinoma.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koutsounas, Ioannis
- Κουτσουνάς, Ιωάννης
Subjects
dc:subject × 16- Πυρηνικός υποδοχέας
- Επιβίωση ασθενών
- Ανοσοϊστοχημεία
- Κλινικοπαθολογοανατομικές παράμετροι
- Καρκίνος παγκρέατος
- Nuclear receptor
- PXR
- RXR
- Patients' survival
- Immunochistochemistry
- Clinicopathological parameters
- Pancreatic cancer
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41710